Page 8 - Exact Sciences News Today

Exact Sciences Corp. (NASDAQ: EXAS) shares hiked Wednesday. The company, a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged ...

A next-generation multitarget stool DNA test for colorectal cancer screening had higher sensitivity but lower specificity than a currently available FIT, according to the large prospective BLUE-C study.

13.03.2024 - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, Next-Generation ... Seite 1

A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.The<a class="excerpt-read-more" href="https://whdh.com/news/a-blood-test-for-colon-cancer-performed-well-in-a-study-expanding-options-for-screening/">Read More</a>

Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed 20,000-participant BLUE-C study included...

A blood test for colon cancer performed well in a study, offering a new kind of screening.

The new test detected 94% of cancers and was 91% accurate in determining who didn’t have cancer, up from 92% cancer sensitivity and 87% specificity for the original Cologuard.

WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- In a powerful display of unity, Fight Colorectal Cancer (Fight CRC) is hosting the 18th Ann...

They won't lag the market forever.

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.